Search Results
Your search for The A,The A matches 32804 pages
Showing 32201 - 32250Long-Term Survivors of Childhood Cancer Exhibit Vascular Endothelial Damage
In a study reported in Journal of Clinical Oncology, Cornelia A.J. Brouwer, of the University Medical Center Groningen in the Netherlands, and colleagues assessed vascular parameters in long-term childhood cancer survivors and sibling controls. They found that survivors who had received...
Lactation May Be Linked to Triple-Negative Breast Cancer in Mexican Women
Scientific data suggest that a woman reduces her risk of breast cancer by breastfeeding, having multiple children, and giving birth at a younger age. However, a study led by the University of California, San Diego School of Medicine, indicates that women of Mexican descent may not fit that profile. ...
Genetic Anti-Inflammatory Defect May Predispose Children to Lymphoma
New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, reveal an important association between the genetic defect, which causes chronic intestinal...
Oral CMX001 100 mg Twice Weekly Reduces Cytomegalovirus Events in Patients Receiving Hematopoietic Cell Transplants
The anti-cytomegalovirus agent CMX001 is an oral lipid acyclic nucleoside phosphonate that is absorbed in the small intestine and transported throughout the body as a phospholipid. It is converted intracellularly to cidofovir diphosphate, but unlike cidofovir, is not a substrate of organic ion...
Breast Cancer Rates Are Rising Among African American Women
Although, historically, white women aged 40 years and older have had the highest incidence rates of breast cancer, the rising rate of breast cancer among African American women—especially among women aged 50 to 59—is narrowing the gap, according to a study by American Cancer Society...
Addition of Rituximab Does Not Improve Outcome in Aggressive B-Cell Lymphoma With Skeletal Involvement, but Radiotherapy Benefit Found
In a retrospective analysis of German High-Grade Non-Hodgkin Lymphoma Study Group trials reported in Journal of Clinical Oncology, Gerhard Held, MD, of Saarland University Medical School in Homburg, and colleagues assessed the impact of rituximab (Rituxan) and radiotherapy on outcome in patients...
ASCO Releases Statement on the Impact of the Government Shutdown on Cancer Care
All nonessential government services were suspended at midnight after Congress failed to reach a budget compromise to keep the government funded before the start of the new fiscal year beginning on October 1, 2013. ASCO issued a statement today in response to the government shutdown and will be...
ECC 2013: French Study Finds Routine PSA Screening Does More Harm Than Good
There is no consensus on the value of routine prostate-specific antigen (PSA) screening. Weighing in on this issue, investigators presented a study at the European Cancer Congress 2013 in Amsterdam (Abstract 1481) suggesting that population-based PSA screening does more harm than good. The...
Treatment With Losartan May Improve Delivery of Chemotherapy Drugs in Tumors
Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In a report published in Nature Communications, investigators from Massachusetts General Hospital (MGH) described how the angiotensin...
Long-Term Results of UK START Trials Support Hypofractionated Adjuvant Radiotherapy in Invasive Early Breast Cancer
The 5-year results of the UK Standardisation of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in fewer, larger doses were at least as safe and effective as the historical standard regimen of 50 Gy in 25 fractions as adjuvant therapy for early breast...
ECC 2013: Strong Showing for Ado-Trastuzumab Emtansine in Heavily Pretreated Advanced HER2-Positive Breast Cancer
Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab (Kadcyla, previously known as T-DM1) extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including trastuzumab...
ECC 2013: TP53 Status Predicts Benefit From Neoadjuvant Cetuximab in Rectal Cancer
In a retrospective analysis of the randomized phase II EXPERT-C trial presented at the European Cancer Congress 2013 (Abstract LBA7), TP53 emerged as a strong, independent predictive biomarker for the benefit of cetuximab (Erbitux) in high-risk, locally advanced rectal cancer, according to...
ECC 2013: PI3KCA-Mutant Tumors Not Likely to Respond to Neoadjuvant HER2 Blockade
In patients with early breast cancer receiving anti-HER2 therapy in the NeoALTTO trial, mutations in PIK3CA were associated with lower rates of pathologic complete response, Jose Baselga, MD, reported at the European Cancer Congress 2013 (Abstract 1859) in Amsterdam. In patients treated with the...
ECC 2013: Novel Anti-PD-L1 Antibody Achieves Durable Responses in Phase I Study of Patients With Metastatic NSCLC, Smokers Included
For the first time, an immunotherapy shows promise in smokers with non–small cell lung cancer (NSCLC). The engineered monoclonal antibody MPDL3280A achieved encouraging and durable responses in a phase I study in metastatic NSCLC in smokers and nonsmokers, and with squamous and adenocarcinoma ...
Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds
Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...
ECC 2013: Continuous Combined Hormone Replacement Therapy Protects Against Endometrial Cancer
According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA13) by Rowan Chlebowski, MD,...
ECC 2013: Radiation to Chest Lymph Nodes Improves Survival in Early Breast Cancer
Extending radiation to the lymph nodes behind the sternal wall and above the collarbone extends overall survival in patients with stage I to III breast cancer and does not increase toxicity compared to conventional locoregional radiation therapy, according to 10-year results of an international...
FDA Approves Neoadjuvant Pertuzumab for Early-Stage Breast Cancer
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel for patients with early-stage breast cancer in the neoadjuvant setting. Pertuzumab is the first FDA-approved drug for the neoadjuvant...
ECC 2013: Molecular Sequencing Identifies Drug Targets for Cancers of Unknown Primary Origin
Cancers of unknown primary origin pose a treatment dilemma for oncologists and a great deal of anxiety for patients and their families. A study reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA39) shows that molecular profiling can identify targetable mutations in up to 80%...
ECC 2013: Multiple Studies Validate Long-Term Survival Benefit of Ipilimumab in Melanoma
There is no longer any doubt that for the treatment of metastatic or locally advanced melanoma, ipilimumab (Yervoy) conveys long-term survival benefits, according to studies presented at the European Cancer Congress 2013. In the largest survival analysis of the CTLA-4 monoclonal antibody to date...
Telomere Length May Be a Prognostic Marker for Prostate Cancer
Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...
Addition of Vorinostat to Bortezomib Results in Small Progression-Free Survival Advantage in Previously-Treated Multiple Myeloma
In a phase III study (VANTAGE 088 trial) reported in The Lancet Oncology, Meletios Dimopolous, MD, of the University of Athens, and colleagues assessed the addition of the oral HDAC inhibitor vorinostat (Zolinza) to bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma. The...
Repurposed Antidepressants May Have Potential to Treat Small Cell Lung Cancer
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small cell lung cancer, according to a study published in Cancer Discovery. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and ...
Intensity-Modulated Radiotherapy Associated With Superior Overall Cosmesis at 5 Years in Patients With Early Breast Cancer
Interim results of the Cambridge Breast Intensity-Modulated Radiotherapy trial indicated that intensity-modulated radiotherapy was associated with significantly reduced skin telangiectasia compared with standard radiotherapy at 2 years in patients with early breast cancer. The trial included a...
Denosumab Increases Bone Metastasis-Free Survival According to PSA Doubling Time in Men With Nonmetastatic Castration-Resistant Prostate Cancer
In a recently reported phase III trial, denosumab (Xgeva) significantly increased bone metastasis–free survival and delayed time to first bone metastasis but did not improve overall survival compared with placebo in men with nonmetastatic castration-resistant prostate cancer and baseline...
ASTRO: Protecting Hippocampus During Whole-Brain Radiation Substantially Reduces Rate of Memory Loss in Cancer Patients
Protecting the stem cells that reside in and around the hippocampus substantially reduces the rate of cancer patients' memory loss during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the phase II clinical trial of...
Higher Post-Treatment FDG-PET Standardized Uptake Value Associated With Poorer Survival in Locally Advanced NSCLC
In a trial (ACRIN 6668/RTOG 0235 trial) reported in Journal of Clinical Oncology, Mitchell Machtay, MD, of Case Western Reserve University, and colleagues assessed the relationship between standardized uptake value for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and survival in...
Increases in Melanoma Incidence and Mortality Unremitting Over 6 Decades, Study Finds
In a study reported in Journal of Clinical Oncology, Alan C. Geller, MPH, RN, of the Harvard School of Public Health, and colleagues assessed long-term trends in the incidence and mortality of melanoma in Connecticut, a state with complete and consistent tumor registration. They found...
For Pregnant Women With Lymphoma, Standard Combination Chemotherapy Given After First Trimester Associated With Few Complications
Lymphoma is the fourth most frequent cancer to occur during pregnancy. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, of Tufts University Medical School, and colleagues examined treatment, complications, and outcomes for Hodgkin lymphoma...
ASTRO: Intensity Modulated Proton Therapy May Preserve Quality of Life in Patients With Oropharyngeal Cancer
A new study from researchers at The University of Texas MD Anderson Proton Therapy Center found that the use of feeding tubes in patients with oropharyngeal cancer treated with intensity modulated proton therapy decreased by more than 50% compared to patients treated with intensity modulated...
Large Retrospective Study Finds Association Between Marriage and Cancer Outcomes
New results from a large retrospective study of the National Cancer Institute’s SEER database, published in the Journal of Clinical Oncology, show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients. Researchers also found...
Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...
Phase II Study Shows Activity of Selective Aurora A Kinase Inhibitor Alisertib in Relapsed/Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphoma
Aurora A kinase is overexpressed in aggressive lymphomas and may correlate with more histologically aggressive forms of disease. In a phase II study reported in Journal of Clinical Oncology, Jonathan W. Friedberg, MD, of University of Rochester Wilmot Cancer Center, and colleagues assessed the...
Colonoscopy Associated With Reduction in Overall, Distal, and Proximal Colorectal Cancer Incidence and Mortality
Colonoscopy and sigmoidoscopy have been shown to provide protection against colorectal cancer, but the magnitude and duration of protection, particularly against proximal colon cancer, remain undefined. A study of long-term colorectal cancer incidence and mortality after lower endoscopy reported in ...
Sunscreen Use Infrequently Discussed With Patients, Even Those With History of Skin Cancer
Although the incidence of skin cancer is increasing, “the rate at which physicians are mentioning sunscreen at patient visits is quite low, even for patients with a history of skin cancer,” according to an analysis of data from more than 18.30 billion patient visits....
Myeloma Foundation Launches Open Access Gateways to Accelerate Drug Development
The Multiple Myeloma Research Foundation (MMRF) has announced two open access gateways, the MMRF Researcher Gateway, which will upload genomic data as it becomes available and make it accessible to all researchers, and the MMRF CoMMunity Gateway, which will aggregate subtypes of myeloma patients...
ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone
When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
USPSTF Issues Final Recommendation Statement on Medications for the Risk Reduction of Primary Breast Cancer in Women
The U.S. Preventive Services Task Force (USPSTF) released today its final recommendation statement on medications to reduce the risk of primary breast cancer in women. Clinicians are recommended to prescribe risk-reducing medications, such as tamoxifen or raloxifene, for women who are at increased...
HERA Trial Shows No Benefit of 2 Years vs 1 Year of Trastuzumab, Significant Survival Benefits of 1 Year vs Observation in Early Breast Cancer
As reported in The Lancet by Aron Goldhirsch, MD, of the European Institute of Oncology in Milan, and colleagues, 2 years of trastuzumab (Herceptin) showed no advantage over 1 year of trastuzumab treatment in patients with HER2-positive early breast cancer in the phase III HERA trial. An update of...
ASTRO: Cisplatin Plus Radiation Therapy for Advanced Cervical Cancer Improves Disease-Free Survival vs Radiotherapy Alone
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy and high–dose rate brachytherapy for stage IIIB cervical cancer is beneficial, according to research presented on September 22, 2013, at the American Society for Radiation Oncology’s 55th Annual Meeting...
ASTRO: Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...
ASTRO: Long-Term Androgen Deprivation in Patients With Intermediate-Risk Prostate Cancer Does Not Improve Overall Survival
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...
Childhood Cancer Survivors Who Received Nephrotoxic Therapy May Be at Greater Risk for Late Renal Problems
A large study assessing glomerular function in adult survivors of childhood cancers who were treated with certain chemotherapy drugs or kidney surgery found that they had worse kidney function, which did not recover over time, compared with adult survivors who were not given nephrotoxic therapy....
Antiviral Treatment Improves Recurrence-Free and Overall Survival in HBV-Related Hepatocellular Carcinoma
Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma have poor postoperative prognosis. In a study reported in Journal of Clinical Oncology, Jianhua Yin, MD, of the Second Military Medical University in Shanghai, and colleagues assessed the effects of nucleotide/nucleoside analog...
NCCN: Practical Considerations in Selecting Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
Although imatinib (Gleevec) is the initial therapy for chronic myeloid leukemia (CML), several second-generation tyrosine kinase inhibitors are now approved for the treatment of this disease. Michael Millenson, MD, of Fox Chase Cancer Center in Philadelphia, reviewed practical considerations in...
NCCN: PET-Guided Therapy for Hodgkin Lymphoma Moving Into Clinical Practice
Interim positron emission tomography (PET) scan is being used to guide risk-adapted therapy in patients with early-stage and advanced-stage Hodgkin lymphoma for clinical research at academic centers, and experts predict that this will become standard of care in clinical practice. At the NCCN 8th...
Mindfulness-Based Stress Reduction Superior to Supportive-Expressive Therapy for Distressed Survivors of Breast Cancer
Mindfulness-based cancer recovery was shown in to be superior to supportive-expressive group therapy decreasing symptoms of stress and improving overall quality of life and social support among survivors of stage I to III breast cancer who were distressed, according to a study reported in Journal...
Pomalidomide Produces ‘Impressive Results’ in Patients With Multiple Myeloma Who Are Refractory to Bortezomib and Lenalidomide
The second-generation immunomodulatory drug pomalidomide (Pomalyst) “has shown impressive results in patients with multiple myeloma who are refractory to lenalidomide and bortezomib,” according to a review of clinical data leading to the drug’s approval by the U.S. Food and Drug...
Researchers Uncover Root Cause of Multiple Myeloma Relapse
Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...
